Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
NCT04217057
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class
Stopped
Insufficient funding/staff
Conditions
Head and Neck Cancer
Interventions
DRUG:
64Cu-DOTA-ECL1i
Sponsor
Washington University School of Medicine
Collaborators
[object Object]
[object Object]